An announcement from Crispr Therapeutics AG ( (CRSP) ) is now available.
On March 24, 2025, Julianne Bruno, the Chief Operating Officer of CRISPR Therapeutics, announced her resignation effective April 11, 2025, to pursue external opportunities. Her departure is not due to any disagreement with the company. Bruno has been a key figure in advancing the company’s hematology and oncology programs and other initiatives. Her resignation marks a significant transition for CRISPR Therapeutics, which continues to strengthen its position in the biopharmaceutical industry through strategic partnerships and innovative gene-editing solutions.
More about Crispr Therapeutics AG
CRISPR Therapeutics is a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases. The company has a diverse portfolio targeting hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. Known for its pioneering work in CRISPR/Cas9 gene-editing technology, CRISPR Therapeutics has achieved significant milestones, including the approval of the first-ever CRISPR-based therapy, CASGEVY®, for sickle cell disease and beta thalassemia. The company is headquartered in Zug, Switzerland, with operations in the U.S.
YTD Price Performance: -1.30%
Average Trading Volume: 2,104,276
Technical Sentiment Signal: Buy
Current Market Cap: $3.66B
For an in-depth examination of CRSP stock, go to TipRanks’ Stock Analysis page.